Inside A Phase III Disappointment: Santhera Reduced Target Population, Now Needs Another Trial

FDA seemed on board with Swiss drugmaker's plans for study of Duchenne muscular dystrophy candidate Raxone, but didn't look too kindly on firm's decision to drop subjects using concomitant glucocorticoids.

Santhera Pharmaceuticals AG’s decision to drop steroid-using patients from its study of Duchenne muscular dystrophy candidate Raxone (idebenone) appears to have cost the drugmaker from gaining accelerated approval for patients not using steroids.

Although the Swiss drugmaker previously began its Phase III trial with both steroid non-using and using subgroups, the study was...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from R&D

More from Pink Sheet